article New models for intranasal drug delivery 6 August 2021 | By Dr Jon Lenn (MedPharm), Dr Jon Volmer (MedPharm) In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
news Polymerised oestrogen provides neuroprotection in pre-clinical study 23 March 2021 | By Victoria Rees (Drug Target Review) The polymerised form of oestrogen has shown success in mice at preventing further damage to the spinal cord after injury.
news Cannabinoids could reduce essential tremors in patients 22 March 2021 | By Victoria Rees (Drug Target Review) A synthetic cannabinoid has shown promise as a treatment for involuntary tremors by activating astrocytes in mouse models.
news Hymecromone can suppress neuroinflammation in astrocytes, study shows 1 March 2021 | By Victoria Rees (Drug Target Review) Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
news CNS target could lead to development of drugs for diabetes 11 February 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
news SARS-CoV-2 infects CNS and damages brain tissue, study shows 13 January 2021 | By Victoria Rees (Drug Target Review) Researchers have shown in cells and models that the central nervous system and neurons can become a target of SARS-CoV-2 infection.
news Novel Alzheimer’s vaccine shows promise in murine models 21 October 2020 | By Hannah Balfour (Drug Target Review) Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
news Epigenetic marks could be the target of future Alzheimer’s therapies 2 October 2020 | By Hannah Balfour (Drug Target Review) New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
news Novel molecule restores lost connections in spinal cords and brains of mice 14 September 2020 | By Victoria Rees (Drug Target Review) Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
news Researchers develop promising new drug candidates to treat ALS 2 September 2020 | By Victoria Rees (Drug Target Review) Scientists have shown that a Selenium-based drug-molecule called ebselen and other novel compounds can delay ALS onset in mouse models.
news COVID-19 poses threat to entire nervous system, says study 15 June 2020 | By Victoria Rees (Drug Target Review) Following an analysis of scientific literature, researchers say that COVID-19 may affect the entire nervous system, including the brain, spinal cord, nerves and muscles.
news High-speed microscope can capture brain signals and calcium concentrations 23 March 2020 | By Hannah Balfour (Drug Target Review) The novel technology allows researchers to create three-dimensional images of signal propagation and calcium concentration changes in the neocortex of live mice.
article Exploring future spinal cord injury therapies 11 March 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
news BT13 molecule shows promise for halting Parkinson’s 18 February 2020 | By Nikki Withers (Drug Target Review) A molecule has been shown to increase dopamine levels in the brains of mice, offering hope for stopping the progression of Parkinson’s.
news CNS tumour aggressiveness reduced with new molecule 8 November 2019 | By Rachael Harper (Drug Target Review) A microRNA inhibitor has been identified which reduced the sizes of aggressive CNS tumours and improved survival in mice.